Colony-Stimulating Factors for Febrile Neutropenia during Cancer Therapy

被引:122
|
作者
Bennett, Charles L. [1 ,2 ,3 ,4 ]
Djulbegovic, Benjamin [5 ,6 ,7 ]
Norris, LeAnn B. [1 ,2 ,3 ,4 ]
Armitage, James O. [8 ]
机构
[1] Univ S Carolina, South Carolina Coll Pharm, South Carolina Ctr Econ Excellence Medicat Safety, Columbia, SC 29208 USA
[2] Univ S Carolina, South Carolina Coll Pharm, Southern Network Adverse React SONAR, Columbia, SC 29208 USA
[3] Med Univ S Carolina, Hollings Canc Ctr, Charleston, SC 29425 USA
[4] William Jennings Bryan Dorn Vet Affairs Med Ctr, Columbia, SC USA
[5] Univ S Florida, Morsani Coll Med, Ctr Evidence Based Med & Hlth Outcome Res, Clin & Translat Sci Inst,Dept Med, Tampa, FL USA
[6] H Lee Moffitt Canc Ctr & Res Inst, Dept Hematol, Tampa, FL USA
[7] H Lee Moffitt Canc Ctr & Res Inst, Dept Hlth Outcomes & Behav, Tampa, FL USA
[8] Univ Nebraska, Omaha Sch Med, Omaha, NE 68182 USA
来源
NEW ENGLAND JOURNAL OF MEDICINE | 2013年 / 368卷 / 12期
关键词
ACUTE MYELOID-LEUKEMIA; BONE-MARROW-TRANSPLANTATION; NON-HODGKIN-LYMPHOMA; CELL LUNG-CANCER; BREAST-CANCER; MYELODYSPLASTIC SYNDROME; CLINICAL-TRIALS; GROWTH-FACTORS; SOLID TUMORS; DOSE-DENSE;
D O I
10.1056/NEJMct1210890
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
A 55-year-old, previously healthy woman received a diagnosis of diffuse large-B-cell lymphoma after the evaluation of an enlarged left axillary lymph node obtained on biopsy. She had been asymptomatic except for the presence of enlarged axillary lymph nodes, which she had found while bathing. She was referred to an oncologist, who performed a staging evaluation. A complete blood count and test results for liver and renal function and serum lactate dehydrogenase were normal. Positron-emission tomography and computed tomography (PET-CT) identified enlarged lymph nodes with abnormal uptake in the left axilla, mediastinum, and retroperitoneum. Results on bone marrow biopsy were normal. The patient's oncologist recommends treatment with six cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone with rituximab (CHOP-R) at 21-day intervals. Is the administration of prophylactic granulocyte colony-stimulating factor (G-CSF) with the first cycle of chemotherapy indicated?
引用
收藏
页码:1131 / 1139
页数:9
相关论文
共 50 条
  • [31] Is febrile neutropenia prophylaxis with granulocyte-colony stimulating factors economically justified for adjuvant TC chemotherapy in breast cancer?
    Chris Skedgel
    Daniel Rayson
    Tallal Younis
    Supportive Care in Cancer, 2016, 24 : 387 - 394
  • [32] Is febrile neutropenia prophylaxis with granulocyte-colony stimulating factors economically justified for adjuvant TC chemotherapy in breast cancer?
    Skedgel, Chris
    Rayson, Daniel
    Younis, Tallal
    SUPPORTIVE CARE IN CANCER, 2016, 24 (01) : 387 - 394
  • [33] Cost-effectiveness of prophylactic granulocyte colony-stimulating factor for febrile neutropenia in breast cancer patients receiving FEC-D
    Esther K. Lee
    William W. L. Wong
    Maureen E. Trudeau
    Kelvin K. W. Chan
    Breast Cancer Research and Treatment, 2015, 150 : 169 - 180
  • [34] Use of colony-stimulating factor primary prophylaxis and incidence of febrile neutropenia from 2010 to 2016: a longitudinal assessment
    Weycker, Derek
    Bensink, Mark
    Lonshteyn, Alexander
    Doroff, Robin
    Chandler, David
    CURRENT MEDICAL RESEARCH AND OPINION, 2019, 35 (06) : 1073 - 1080
  • [35] The prophylactic effects of long-acting granulocyte colony-stimulating factor for febrile neutropenia in newly diagnosed patients with epithelial ovarian cancer: a randomised controlled study
    Li, Lei
    Ma, Shuiqing
    Wu, Ming
    Tan, Xianjie
    Zhong, Sen
    Lang, Jinghe
    BMJ SUPPORTIVE & PALLIATIVE CARE, 2019, 9 (04) : 373 - 380
  • [36] Primary Granulocyte Colony-Stimulating Factor Prophylaxis During the First Two Cycles Only or Throughout All Chemotherapy Cycles in Patients With Breast Cancer at Risk for Febrile Neutropenia
    Aarts, Maureen J.
    Peters, Frank P.
    Mandigers, Caroline M.
    Dercksen, M. Wouter
    Stouthard, Jacqueline M.
    Nortier, Hans J.
    van Laarhoven, Hanneke W.
    van Warmerdam, Laurence J.
    van de Wouw, Agnes J.
    Jacobs, Esther M.
    Mattijssen, Vera
    van der Rijt, Carin C.
    Smilde, Tineke J.
    van der Velden, Annette W.
    Temizkan, Mehmet
    Batman, Erdogan
    Muller, Erik W.
    van Gastel, Saskia M.
    Borm, George F.
    Tjan-Heijnen, Vivianne C. G.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (34) : 4290 - U20
  • [37] Clinical Outcomes of Secondary Prophylactic Granulocyte Colony-Stimulating Factors in Breast Cancer Patients at a Risk of Neutropenia with Doxorubicin and Cyclophosphamide-Based Chemotherapy
    Choi, Jae Hee
    Geum, Min Jung
    Kang, Ji Eun
    Park, Nam Gi
    Oh, Yun Kyoung
    Rhie, Sandy Jeong
    PHARMACEUTICALS, 2021, 14 (11)
  • [38] Incidence of chemotherapy-induced neutropenia and current practice of prophylaxis with granulocyte colony-stimulating factors in cancer patients in Spain: a prospective, observational study
    Jolis, L.
    Carabantes, F.
    Pernas, S.
    Cantos, B.
    Lopez, A.
    Torres, P.
    Funes, C.
    Caballero, D.
    Benedit, P.
    Salar, A.
    EUROPEAN JOURNAL OF CANCER CARE, 2013, 22 (04) : 513 - 521
  • [39] Evaluating the Prognostic Role of Monocytopenia in Chemotherapy-Induced Febrile Neutropenia Patients Treated with Granulocyte Colony-Stimulating Factor
    Alshari, Osama
    Al Zu'bi, Yazan O.
    Al Sharie, Ahmed H.
    Wafai, Farouk H.
    Aleshawi, Abdelwahab J.
    Atawneh, Farah H.
    Obeidat, Hasan A.
    Daoud, Majd N.
    Khrais, Mohammad Z.
    Albals, Dima
    Tubaishat, Faize
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2021, 17 : 963 - 973
  • [40] Impact of colony-stimulating factors to reduce febrile neutropenic events in breast cancer patients receiving docetaxel plus cyclophosphamide chemotherapy
    Alexandre Chan
    Wing Hang Fu
    Vivianne Shih
    Jurja Chua Coyuco
    Sze Huey Tan
    Raymond Ng
    Supportive Care in Cancer, 2011, 19 : 497 - 504